emapalumab | Gamifant® (emapalumab-lzsg)

Keyword	CPC	PCC	Volume	Score	Length of keyword
emapalumab	1.3	0.2	2168	98	10

Keyword	CPC	PCC	Volume	Score
emapalumab	0.97	1	5541	16
emapalumab hlh	1.59	0.4	1489	74
emapalumab ema	1.55	0.5	3804	15
emapalumab-lzsg	1.36	0.4	5753	16
emapalumab cost	0.73	0.6	7655	27
emapalumab package insert	0.44	1	1801	6
emapalumab sle	0.61	0.7	1969	21
emapalumab spc	1.4	0.3	8911	58
emapalumab label	0.39	1	5323	10
emapalumab hlh nejm	1.69	0.1	3895	85
monoclonal emapalumab for hlh	0.54	0.6	7836	85
emapalumab secondary hlh	0.38	0.3	2804	80
emapalumab manufacturer	0.29	0.9	9605	31
emapalumab administration	1.03	0.4	3818	58

Search Results related to emapalumab on Search Engine

Gamifant® (emapalumab-lzsg) | For Healthcare Professionals
gamifant.com

https://www.gamifant.com/

WEBGamifant ® (emapalumab-lzsg) is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

DA: 53 PA: 92 MOZ Rank: 72

Emapalumab - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Emapalumab

WEBEmapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which has no cure. The most common side effects include infections, hypertension, infusion-related reactions, and pyrexia.

DA: 3 PA: 40 MOZ Rank: 50

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1911326

WEBMay 6, 2020 · Emapalumab is a fully human IgG1 anti–interferon-γ monoclonal antibody that binds free and receptor-bound interferon-γ (inhibiting receptor dimerization and transduction of interferon-γ...

DA: 40 PA: 37 MOZ Rank: 89

Emapalumab for the treatment of relapsed/refractory hemophagocytic
ashpublications.org

https://ashpublications.org/blood/article/134/21/1783/374991/Emapalumab-for-the-treatment-of-relapsed

WEBNov 21, 2019 · Conclusions. Emapalumab is the first cytokine-targeting therapy approved specifically for the treatment of HLH. This treatment involves the infusion of a monoclonal antibody targeting IFN-γ along with dexamethasone, and resulted in a high overall response rate in a small pediatric population of patients with primary HLH.

DA: 50 PA: 55 MOZ Rank: 76

FDA approves emapalumab for hemophagocytic lymphohistiocytosis
fda.gov

https://www.fda.gov/drugs/fda-approves-emapalumab-hemophagocytic-lymphohistiocytosis

WEBOn November 20, 2018, the Food and Drug Administration approved emapalumab (GAMIFANT, Novimmune SA), a monoclonal antibody that binds and neutralizes interferon gamma, for adult and pediatric...

DA: 4 PA: 100 MOZ Rank: 37

Emapalumab Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/emapalumab.html

WEBJul 20, 2023 · What is emapalumab? Emapalumab is used together with a medicine called dexamethasone to treat hemophagocytic lymphohistiocytosis (HLH), a rare disease that is sometimes inherited. HLH causes your immune system to attack healthy blood cells, which can lead to serious or life-threatening side effects on your spleen or liver.

DA: 32 PA: 67 MOZ Rank: 15

FDA approves first treatment specifically for patients with rare and
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-specifically-patients-rare-and-life-threatening-type-immune-disease

WEBThe U.S. Food and Drug Administration today approved Gamifant (emapalumab-lzsg) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic...

DA: 80 PA: 20 MOZ Rank: 53

Gamifant (emapalumab) dosing, indications, interactions, adverse
medscape.com

https://reference.medscape.com/drug/gamifant-emapalumab-1000291

WEBMedscape - Hemophagocytic lymphohistiocytosis dosing for Gamifant (emapalumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules,...

DA: 2 PA: 76 MOZ Rank: 100

Emapalumab for the treatment of relapsed/refractory …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938935/

WEBNov 11, 2019 · Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-γ (IFN-γ), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or …

DA: 78 PA: 77 MOZ Rank: 44

FDA approves Gamifant® (emapalumab), the first and only ... - Sobi
sobi.com

https://www.sobi.com/en/press-releases/fda-approves-gamifantr-emapalumab-first-and-only-treatment-primary-haemophagocytic

WEBNov 20, 2018 · Primary haemophagocytic lymphohistiocytosis (HLH) is an ultra-rare, rapidly progressive, often-fatal syndrome of hyperinflammation in which massive hyperproduction of interferon gamma (IFNy) is thought to drive immune system hyperactivation, ultimately leading to organ failures.

DA: 88 PA: 3 MOZ Rank: 45